What is the best treatment option in postmenopausal, hormone responsive breast cancer patients with isolated bone metastases.
Indian J Cancer
;
2013 Jan-Mar; 50(1): 52-57
Article
in English
| IMSEAR
| ID: sea-147320
ABSTRACT
Background:
Bone is the most common metastatic site for breast cancer.Aim:
To determine the effectiveness of addition of chemotherapy to hormonal therapy in postmenopausal hormone receptor-positive breast cancer patients with isolated bone metastases. Materials andMethods:
Between June 2001 and January 2007, 101 patients were classified into two groups according to initial treatment modalities; patients who received hormonotherapy only (group I) and chemotherapy followed by hormonotherapy (group II). The effect of treatment choice on clinical course, time to progression, and overall survival were evaluated.Results:
There were 70 patients in group I and 31 patients in group II. Bone metastases in 27 patients (26.7%) were synchronous and the remainder were metachronous. The median follow-up time was 41 months. The two groups showed similar results when patients' tumor characteristics were compared. However, 81% of synchronous cases had upfront chemotherapy following hormonotherapy, whereas this ratio was only 12% in the metachronous group. All patients received systemic antiresorptive bisphosphonates whereas only 24 patients required palliative radiotherapy at some time during the course of their disease. In groups I and II, the median time to progression was 12 and 16 months (P 0.96) and median overall survival was 41 and 40 months (P 0.79), respectively. In HER-2-positive patients, a trend of prolongation of overall survival was observed in group II, but it was not statistically significant (P 0.12).Conclusions:
Anti-hormonal therapy still seems to be considered as the ideal treatment of choice for postmenapousal breast cancer patients with isolated bone metastases.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Bone Neoplasms
/
Aged, 80 and over
/
Breast Neoplasms
/
Aged
/
Female
/
Humans
/
Carcinoma
/
Survival Analysis
/
Follow-Up Studies
/
Chemotherapy, Adjuvant
Type of study:
Observational study
/
Prognostic study
Limits:
Aged80
Language:
English
Journal:
Indian J Cancer
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS